Idun Pharmaceuticals Initiates Phase 2 Clinical Study of IDN-6556 in Hepatitis

[Guest guest]

Idun Pharmaceuticals Initiates Phase 2 Clinical Study of IDN-6556 in Hepatitis C

Virus

Wednesday July 28, 9:07 am ET

SAN DIEGO, July 28 /PRNewswire/ -- Idun Pharmaceuticals, Inc. today announced

that it has initiated a Phase 2 clinical study of IDN-6556 in patients infected

with hepatitis C virus (HCV). The dose-response study will evaluate whether

IDN-6556 can decrease the liver damage that occurs from hepatitis, an

inflammation of the liver, which can be caused by HCV infection. Participants in

this trial will have previously failed to respond to existing drugs for HCV and

will receive one of several doses of IDN-6556, or placebo, given orally as a

monotherapy for 3 months. This study will be conducted at fifteen sites in the

U.S. and is expected to enroll up to 200 patients.

The initiation of this Phase 2 clinical study of IDN-6556 is an important

milestone in the development of this exciting new candidate for the treatment of

diseases of the liver, " said Shapiro, M.D., Idun's Chief Medical Officer.

" We believe that IDN-6556 has considerable potential to treat not only HCV but

several other liver diseases based on the encouraging data from the previous

clinical experiences. These data have been presented at a number of recent

medical meetings including the American Association for the Study of Liver

Disease, the European Association for the Study of the Liver and Digestive

Disease Week. The current Phase 2 trial seeks to repeat and expand on the

results observed in the previous trial and should provide important additional

information about safety, dosage and markers of disease progression. "

Additional information about participating in this clinical trial can be

obtained at the Idun web site at www.idun.com.

http://biz./prnews/040728/law019_1.html

[Guest guest]

Idun Pharmaceuticals Initiates Phase 2 Clinical Study of IDN-6556 in Hepatitis C

Virus

Wednesday July 28, 9:07 am ET

SAN DIEGO, July 28 /PRNewswire/ -- Idun Pharmaceuticals, Inc. today announced

that it has initiated a Phase 2 clinical study of IDN-6556 in patients infected

with hepatitis C virus (HCV). The dose-response study will evaluate whether

IDN-6556 can decrease the liver damage that occurs from hepatitis, an

inflammation of the liver, which can be caused by HCV infection. Participants in

this trial will have previously failed to respond to existing drugs for HCV and

will receive one of several doses of IDN-6556, or placebo, given orally as a

monotherapy for 3 months. This study will be conducted at fifteen sites in the

U.S. and is expected to enroll up to 200 patients.

The initiation of this Phase 2 clinical study of IDN-6556 is an important

milestone in the development of this exciting new candidate for the treatment of

diseases of the liver, " said Shapiro, M.D., Idun's Chief Medical Officer.

" We believe that IDN-6556 has considerable potential to treat not only HCV but

several other liver diseases based on the encouraging data from the previous

clinical experiences. These data have been presented at a number of recent

medical meetings including the American Association for the Study of Liver

Disease, the European Association for the Study of the Liver and Digestive

Disease Week. The current Phase 2 trial seeks to repeat and expand on the

results observed in the previous trial and should provide important additional

information about safety, dosage and markers of disease progression. "

Additional information about participating in this clinical trial can be

obtained at the Idun web site at www.idun.com.

http://biz./prnews/040728/law019_1.html

[Guest guest]

Idun Pharmaceuticals Initiates Phase 2 Clinical Study of IDN-6556 in Hepatitis C

Virus

Wednesday July 28, 9:07 am ET

SAN DIEGO, July 28 /PRNewswire/ -- Idun Pharmaceuticals, Inc. today announced

that it has initiated a Phase 2 clinical study of IDN-6556 in patients infected

with hepatitis C virus (HCV). The dose-response study will evaluate whether

IDN-6556 can decrease the liver damage that occurs from hepatitis, an

inflammation of the liver, which can be caused by HCV infection. Participants in

this trial will have previously failed to respond to existing drugs for HCV and

will receive one of several doses of IDN-6556, or placebo, given orally as a

monotherapy for 3 months. This study will be conducted at fifteen sites in the

U.S. and is expected to enroll up to 200 patients.

The initiation of this Phase 2 clinical study of IDN-6556 is an important

milestone in the development of this exciting new candidate for the treatment of

diseases of the liver, " said Shapiro, M.D., Idun's Chief Medical Officer.

" We believe that IDN-6556 has considerable potential to treat not only HCV but

several other liver diseases based on the encouraging data from the previous

clinical experiences. These data have been presented at a number of recent

medical meetings including the American Association for the Study of Liver

Disease, the European Association for the Study of the Liver and Digestive

Disease Week. The current Phase 2 trial seeks to repeat and expand on the

results observed in the previous trial and should provide important additional

information about safety, dosage and markers of disease progression. "

Additional information about participating in this clinical trial can be

obtained at the Idun web site at www.idun.com.

http://biz./prnews/040728/law019_1.html

[Guest guest]

Idun Pharmaceuticals Initiates Phase 2 Clinical Study of IDN-6556 in Hepatitis C

Virus

Wednesday July 28, 9:07 am ET

SAN DIEGO, July 28 /PRNewswire/ -- Idun Pharmaceuticals, Inc. today announced

that it has initiated a Phase 2 clinical study of IDN-6556 in patients infected

with hepatitis C virus (HCV). The dose-response study will evaluate whether

IDN-6556 can decrease the liver damage that occurs from hepatitis, an

inflammation of the liver, which can be caused by HCV infection. Participants in

this trial will have previously failed to respond to existing drugs for HCV and

will receive one of several doses of IDN-6556, or placebo, given orally as a

monotherapy for 3 months. This study will be conducted at fifteen sites in the

U.S. and is expected to enroll up to 200 patients.

The initiation of this Phase 2 clinical study of IDN-6556 is an important

milestone in the development of this exciting new candidate for the treatment of

diseases of the liver, " said Shapiro, M.D., Idun's Chief Medical Officer.

" We believe that IDN-6556 has considerable potential to treat not only HCV but

several other liver diseases based on the encouraging data from the previous

clinical experiences. These data have been presented at a number of recent

medical meetings including the American Association for the Study of Liver

Disease, the European Association for the Study of the Liver and Digestive

Disease Week. The current Phase 2 trial seeks to repeat and expand on the

results observed in the previous trial and should provide important additional

information about safety, dosage and markers of disease progression. "

Additional information about participating in this clinical trial can be

obtained at the Idun web site at www.idun.com.

http://biz./prnews/040728/law019_1.html